Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
VIR Vir Biotechnology Inc
- Stocks
- Healthcare
- NASDAQ: VIR
Price (delayed)
$5.41
Market cap
$741.95M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.83
Enterprise value
$519.75M
Vir Biotechnology is a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Vir has assembled four technology platforms that are
Highlights
The debt has contracted by 19% YoY and by 3.5% from the previous quarter
The EPS rose by 17% year-on-year and by 2.3% since the previous quarter
Vir Biotechnology's equity has decreased by 28% YoY and by 7% from the previous quarter
VIR's revenue is down by 14% YoY and by 6% from the previous quarter
Key stats
What are the main financial stats of VIR
Market
Valuations
Earnings
Shares outstanding
137.14M
Market cap
$741.95M
Enterprise value
$519.75M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.65
Price to sales (P/S)
9.93
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7
Revenue
$74.21M
Gross profit
$73.36M
Operating income
-$587.17M
Net income
-$521.96M
EBIT
-$523.11M
EBITDA
-$503.3M
Free cash flow
-$450.28M
Per share
Balance sheet
Liquidity
EPS
-$3.83
EPS diluted
-$3.83
Free cash flow per share
-$3.3
Book value per share
$8.35
Revenue per share
$0.54
TBVPS
$10.08
Total assets
$1.4B
Total liabilities
$248.43M
Debt
$90.14M
Equity
$1.15B
Working capital
$922.8M
Debt to equity
0.08
Current ratio
8.71
Quick ratio
8.31
Net debt/EBITDA
0.44
Margins
Efficiency
Dividend
EBITDA margin
-678.3%
Gross margin
98.9%
Net margin
-703.4%
Operating margin
-791.3%
Return on assets
-32.8%
Return on equity
-38.9%
Return on invested capital
-40.8%
Return on capital employed
-40.9%
Return on sales
-704.9%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
VIR stock price
How has the Vir Biotechnology stock price performed over time
Intraday
-3.57%
1 week
-11.02%
1 month
4.24%
1 year
-43.29%
YTD
-26.29%
QTD
-16.51%
Financial performance
How have Vir Biotechnology's revenue and profit performed over time
Revenue
$74.21M
Gross profit
$73.36M
Operating income
-$587.17M
Net income
-$521.96M
Gross margin
98.9%
Net margin
-703.4%
The net income has increased by 15% year-on-year and by 2.1% since the previous quarter
The company's operating income rose by 14% YoY and by 3.6% QoQ
VIR's revenue is down by 14% YoY and by 6% from the previous quarter
The company's gross profit fell by 12% YoY and by 6% QoQ
Price vs fundamentals
How does VIR's price correlate with its fundamentals
Growth
What is Vir Biotechnology's growth rate over time
Valuation
What is Vir Biotechnology stock price valuation
P/E
N/A
P/B
0.65
P/S
9.93
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7
The EPS rose by 17% year-on-year and by 2.3% since the previous quarter
VIR's price to book (P/B) is 80% lower than its 5-year quarterly average of 3.3 and 28% lower than its last 4 quarters average of 0.9
Vir Biotechnology's equity has decreased by 28% YoY and by 7% from the previous quarter
The price to sales (P/S) is 55% lower than the 5-year quarterly average of 21.9 and 33% lower than the last 4 quarters average of 14.8
VIR's revenue is down by 14% YoY and by 6% from the previous quarter
Efficiency
How efficient is Vir Biotechnology business performance
Vir Biotechnology's return on assets has decreased by 18% YoY and by 6% QoQ
Vir Biotechnology's return on equity has decreased by 11% YoY and by 6% QoQ
The return on invested capital has declined by 7% since the previous quarter but it rose by 4.4% year-on-year
The return on sales rose by 3.3% year-on-year but it has declined by 2.8% since the previous quarter
Dividends
What is VIR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for VIR.
Financial health
How did Vir Biotechnology financials performed over time
Vir Biotechnology's total assets has decreased by 27% YoY and by 7% QoQ
The company's total liabilities fell by 24% YoY and by 3.6% QoQ
The debt is 92% less than the equity
Vir Biotechnology's equity has decreased by 28% YoY and by 7% from the previous quarter
The debt has contracted by 19% YoY and by 3.5% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.